Changes of pituitary adenylate cyclase activating polypeptide (PACAP) level in polytrauma patients in the early post-traumatic period

Tamás, Andrea; Tóth, Dénes; Pham, Dániel; Loibl, Csaba; Rendeki, Szilárd; Csontos, Csaba; Rozanovic, Martin; Bogár, Lajos; Polgar, Beata; Németh, József; Gyenesei, Attila; Herczeg, Róbert; Szántó, Zalán; Reglődi, Dóra

doi:10.1016/j.peptides.2021.170645

Cited by 6 publications

(7 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The positive correlation between PACAP-38 and CRP levels are also strengthening the potential biomarker role of PACAP-38 in HF. This theory is further supported by our earlier study, where we detected sigificant positive correlation between PACAP and CRP in polytrauma patients during the acute phase [ 23 ]. However, it is important to note that circulating PACAP-38 levels alone may not be a useful biomarker for individuals suffering from HF; therefore, additional, complementary measures of other cardiac biomarkers may need to be combined with the polypeptide.…”

Section: Discussionsupporting

confidence: 84%

“…Similar PACAP-38 release was observed during some acute severe or life-threatening human diseases, such as acute ST-segment elevation myocardial infarction [ 21 ]. Based on these findings we suppose, that PACAP-38 can be regarded as a general marker that may indicate the severity of the tissue injury, and also as a protective factor, eliciting antioxidant, antiapoptotic and anti-inflammatory effects in response to acute cellular damage [ 23 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

PACAP-38 and PAC1 Receptor Alterations in Plasma and Cardiac Tissue Samples of Heart Failure Patients

Szabò

Sárszegi

Polgar

et al. 2022

IJMS

Self Cite

View full text Add to dashboard Cite

Pituitary adenylate cyclase activating polypeptide-38 (PACAP-38) is a multifunctional neuropeptide, which may play a role in cardioprotection. However, little is known about the presence of PACAP-38 in heart failure (HF) patients. The aim of our study was to measure the alterations of PACAP-38 like immunoreactivity (LI) in acute (n = 13) and chronic HF (n = 33) and to examine potential correlations between PACAP-38 and HF predictors (cytokines, NT-proBNP). Tissue PACAP-38 LI and PAC1 receptor levels were also investigated in heart tissue samples of patients with HF. Significantly higher plasma PACAP-38 LI was detected in patients with acute HF, while in chronic HF patients, a lower level of immunoreactivity was observed compared to healthy controls (n = 13). Strong negative correlation was identified between plasma PACAP-38 and NT-proBNP levels in chronic HF, as opposed to the positive connection seen in the acute HF group. Plasma IL-1 β, IL-2 and IL-4 levels were significantly lower in chronic HF, and IL-10 was significantly higher in patients with acute HF. PACAP-38 levels of myocardial tissues were lower in all end-stage HF patients and lower PAC1 receptor levels were detected in the primary dilated cardiomyopathy group compared to the controls. We conclude that PACAP-38 and PAC1 expression correlates with some biomarkers of acute and chronic HF; therefore, further studies are necessary to explore whether PACAP could be a suitable prognostic biomarker in HF patients.

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Discussionmentioning

confidence: 99%

PACAP-38 and PAC1 Receptor Alterations in Plasma and Cardiac Tissue Samples of Heart Failure Patients

Szabò

Sárszegi

Polgar

et al. 2022

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…PACAP plays a role in neuronal excitability (May et al 2021 ), urinary bladder activity (Girard et al 2021 ), gastrointestinal motility and secretion (Karpiesiuk and Palus 2021 ; Reglodi et al 2018 ; Rytel et al 2021 ), cartilage and bone formation (Jozsa et al 2021 ), and reproduction and embryonal growth (Koves et al 2020 ; Ross et al 2018 ; Shan et al 2021 ) and it also has immunomodulatory functions (Abad and Tan 2018 ). Several studies show that PACAP plays important roles in numerous pathological conditions such as tumor growth and proliferation (D’Amico et al 2021b , c ; Maugeri et al 2018a , 2021 ; Moody et al 2016 ) and nervous system disorders (Moody and Jensen 2021 ) like migraine, schizophrenia, anxiety, and depression (Eslami et al 2021 ; Kormos et al 2016 ; Martelle et al 2021 ; Ross et al 2020 ; Tiihonen et al 2021 ) as well as inflammatory conditions (Moody and Jensen 2021 ; Tamas et al 2021 ), sudden infant death syndrome (Shi et al 2021 ), and hearing loss (Fulop et al 2019 ; Ruel et al 2021 ).…”

Section: Introductionmentioning

confidence: 99%

Distribution of PACAP and PAC1 Receptor in the Human Eye

et al. 2022

View full text Add to dashboard Cite

Pituitary adenylate cyclase–activating polypeptide (PACAP) is a neuropeptide with widespread distribution and diverse biological functions. Several studies show that PACAP has strong cytoprotective effects mediated mostly through its specific PAC1 receptor (PAC1-R) and it plays important roles in several pathological conditions. Its distribution and altered expression are known in various human tissues, but there is no descriptive data about PACAP and its receptors in the human eyebulb. Since PACAP38 is the dominant form of the naturally occurring PACAP, our aim was to investigate the distribution of PACAP38-like immunoreactivity in the human eye and to describe the presence of PAC1-R. Semiquantitative evaluation was performed after routine histology and immunohistochemical labeling on human eye sections. Our results showed high level of immunopositivity in the corneal epithelium and endothelium. Within the vascular layer, the iris and the ciliary body had strong immunopositivity for both PACAP and PAC1-R. Several layers of the retina showed immunoreactivity for PACAP and PAC1-R, but the ganglion cell layer had a special pattern in the immunolabeling. Labeling was observed in the neuropil within the optic nerve in both cases and glial cells displayed immunoreactivity for PAC1-R. In summary, our study indicates the widespread occurrence of PACAP and its specific receptor in the human eye, implying that the results from in vitro and animal studies have translational value and most probably are also present in the human eye.

show abstract

“…Furthermore, there is bidirectional cross–talk between the neuroendocrine and immunological systems via several mediators. PACAP, as the master regulator of stress adaptation, was also found to have immunomodulatory properties in vivo in reducing the harmful effects of septic shock by balancing pro– and anti–inflammatory elements ( 113 , 122 , 123 ). A study examined the alteration of plasma and CSF levels of PACAP in severe traumatic brain injury (TBI).…”

Section: Critical Illnessmentioning

confidence: 99%

Role of endocrine PACAP in age-related diseases

et al. 2023

View full text Add to dashboard Cite

Pituitary adenylate cyclase activating polypeptide (PACAP) is a conserved neuropeptide, which confers diverse anti-aging endocrine and paracrine/autocrine effects, including anti-apoptotic, anti-inflammatory and antioxidant action. The results of the in vivo and in vitro experiments show that increasing emphasis is being placed on the diagnostic/prognostic biomarker potential of this neuropeptide in a wide array of age-related diseases. After the initial findings regarding the presence and alteration of PACAP in different body fluids in physiological processes, an increasing number of studies have focused on the changes of its levels in various pathological conditions associated with advanced aging. Until 2016 – when the results of previous human studies were reviewed – a vast majority of the studies had dealt with age-related neurological diseases, like cerebrovascular and neurodegenerative diseases, multiple sclerosis, as well as some other common diseases in elderly such as migraine, traumatic brain injury and post-traumatic stress disorder, chronic hepatitis and nephrotic syndrome. The aim of this review is to summarize the old and the new results and highlight those ‘classical’ and emerging clinical fields in which PACAP may become subject to further investigation as a diagnostic and/or prognostic biomarker in age-related diseases.

show abstract

Changes of pituitary adenylate cyclase activating polypeptide (PACAP) level in polytrauma patients in the early post-traumatic period

Cited by 6 publications

References 68 publications

PACAP-38 and PAC1 Receptor Alterations in Plasma and Cardiac Tissue Samples of Heart Failure Patients

PACAP-38 and PAC1 Receptor Alterations in Plasma and Cardiac Tissue Samples of Heart Failure Patients

Distribution of PACAP and PAC1 Receptor in the Human Eye

Role of endocrine PACAP in age-related diseases

Contact Info

Product

Resources

About